Afinitor and Ipf - a phase IV clinical study of FDA data

Summary:

Ipf is reported as a side effect among people who take Afinitor (everolimus), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Aromasin, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Ipf when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Ipf?

Ipf is found to be associated with 1,802 drugs and 2,276 conditions by eHealthMe. Check the latest studies of Ipf.

On May, 07, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 68 people (0.16%) have Ipf.

Among these 68 people:

How long have people been on Afinitor when they have Ipf? *

What is the gender of people who have Ipf when taking Afinitor? *

female: 57.58 %
male: 42.42 %

What is the age of people who have Ipf when taking Afinitor? *

What are other drugs people take besides Afinitor? *

What are other side effects people have besides Ipf? *

Dyspnea (difficult or laboured breathing): 31 people, 45.59%
Fever: 23 people, 33.82%
Pneumonia: 18 people, 26.47%
Cough: 18 people, 26.47%
Fatigue (feeling of tiredness): 12 people, 17.65%
Weight Decreased: 12 people, 17.65%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 11 people, 16.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 16.18%
Interstitial Lung Disease: 11 people, 16.18%
Oedema Peripheral (superficial swelling): 10 people, 14.71%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 9 people, 13.24%
Pancreatic Neuroendocrine Tumor: 5 people, 7.35%
Neuroendocrine Tumor: 5 people, 7.35%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 5.88%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 3 people, 4.41%
Metastases To Bone (cancer spreads to bone): 2 people, 2.94%
High Blood Pressure: 2 people, 2.94%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 2 people, 2.94%
Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 2 people, 2.94%
Migraine (headache): 1 person, 1.47%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Ipf?

- Check whether Ipf is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Ipf treatments and more:

Ipf (79,194 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ipf:

Ipf (1,802 drugs)

Browse all the conditions that are associated with Ipf:

Ipf (2,276 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.